LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Japan approval of subcutaneous LEQEMBI for early Alzheimer's signals expanded treatment access.
What changed
Japan approval of subcutaneous LEQEMBI for early Alzheimer's signals expanded treatment access.
Why it matters
Japan approval of subcutaneous LEQEMBI for early Alzheimer's signals expanded treatment access. — impact context not separately stored; see What changed.
← Dashboard
Sep 16, 2026 07:25 AM ET